CD68 and non-small cell lung carcinoma: In addition, a recent study showed that high expression of both CMTM6 and PD-L1, particularly in stromal ICs (CD68 + macrophages) of non-small-cell lung cancer, might identify the patients with the greatest benefit from PD-1 axis blockade [7].